RGO Stock Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Regeneron Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$766.50 |
| 52 Week High | US$807.00 |
| 52 Week Low | US$632.00 |
| Beta | 0.16 |
| 1 Month Change | 0% |
| 3 Month Change | 0.065% |
| 1 Year Change | 14.42% |
| 3 Year Change | 72.29% |
| 5 Year Change | n/a |
| Change since IPO | 7,595.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| RGO | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | 1.2% |
| 1Y | 14.4% | -24.4% | 2.0% |
Return vs Industry: RGO exceeded the German Biotechs industry which returned -26% over the past year.
Return vs Market: RGO exceeded the German Market which returned -1.1% over the past year.
Price Volatility
| RGO volatility | |
|---|---|
| RGO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: RGO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RGO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 12,463 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
Regeneron Pharmaceuticals, Inc. Fundamentals Summary
| RGO fundamental statistics | |
|---|---|
| Market cap | €91.70b |
| Earnings (TTM) | €3.67b |
| Revenue (TTM) | €12.05b |
25.0x
P/E Ratio7.6x
P/S RatioIs RGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGO income statement (TTM) | |
|---|---|
| Revenue | US$13.10b |
| Cost of Revenue | US$6.14b |
| Gross Profit | US$6.95b |
| Other Expenses | US$2.96b |
| Earnings | US$3.99b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 02, 2024
| Earnings per share (EPS) | 37.53 |
| Gross Margin | 53.09% |
| Net Profit Margin | 30.47% |
| Debt/Equity Ratio | 8.0% |
How did RGO perform over the long term?
See historical performance and comparison